• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

A refined microbiome “fingerprint” method tracks sub-strain variants of a single gut microbe strain

May 9, 2022 Microbiome Times

Casey D. Morrow, Ph.D., and colleagues at the University of Alabama at Birmingham previously developed a microbiome “fingerprint” method called WSS that identifies single strains of particular gut bacteria, through analysis of metagenomics data from […]

Pharma & Human Health

Study finds how Acinetobacter baumannii survives without water on hospital surfaces

May 5, 2022 Microbiome Times

The pathogen Acinetobacter baumannii can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Now, a team of Vanderbilt researchers has […]

Pharma & Human Health

New method for probing the bewildering diversity of the microbiome

May 5, 2022 Microbiome Times

In a new study, Qiyun Zhu and his colleagues describe a new method for probing the microbiome in unprecedented detail. The technique provides greater simplicity and ease of use compared with existing approaches. Using the new technique, […]

Pharma & Human Health

Microba Accelerates Cancer Program with New Leads

May 5, 2022 Microbiome Times

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies […]

Pharma & Human Health

Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages

May 3, 2022 Microbiome Times

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the first international approval of a compassionate treatment with its phages, in Sweden. The Swedish Medical Products […]

Finance

Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis

April 28, 2022 Microbiome Times

Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]

Pharma & Human Health

Genetics affects functions of gut microbiome

April 28, 2022 Microbiome Times

New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome. The trillions of individual organisms […]

Pharma & Human Health

Protecting the human intestinal microbiome with synthetic biology

April 18, 2022 Microbiome Times

A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when […]

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

April 15, 2022 Laurence Zitvogel

 

Editor's Choice

Did you miss Probiota Copenhagen 2022? Catch up now!

April 12, 2022 Nina Vinot

With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]

Finance

Microba Life Sciences Completes Successful IPO & Announces Partnership with Ginkgo Bioworks

April 4, 2022 Microbiome Times

Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]

Posts navigation

« 1 … 27 28 29 … 84 »

Sign Up to Free Newsletter

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter